Mineralys Therapeutics (MLYS) CMO Ferguson listed as insider with no trades

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. reported that its Chief Medical Officer, James J. Ferguson III, submitted an initial statement of beneficial ownership as an officer of the company. The report shows no equity transactions or holdings currently reported and includes an exhibit granting a Power of Attorney related to SEC reporting.

Key Terms

Power of Attorney

1 terms

Power of Attorney regulatory

"EX-24 James J. Ferguson III POA"

A power of attorney is a legal document that allows one person to make decisions and act on behalf of another person, often in financial or legal matters. It’s like giving someone a trusted helper or agent the authority to handle important tasks if you are unable to do so yourself. This matters to investors because it can impact how their assets are managed or transferred if they become unable to oversee their affairs.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/12/2026 - 07:33 PM Accepted by SEC EDGAR 08/12/2026 - 07:33 PM Learn about SEC filing dates

FAQ

What does the Mineralys Therapeutics (MLYS) Form 3 for James J. Ferguson III show?

The Form 3 for James J. Ferguson III, Chief Medical Officer of Mineralys Therapeutics (MLYS), reports his status as an officer but discloses no equity holdings or transactions at this time, based on the data provided.

Did Mineralys Therapeutics (MLYS) report any insider share purchases or sales in this Form 3?

No. The insider data for Mineralys Therapeutics (MLYS) show no reported transactions: buy, sell, acquire, dispose, exercise, or gifts are all listed as zero in the transaction summary for James J. Ferguson III.

What position does James J. Ferguson III hold at Mineralys Therapeutics (MLYS)?

James J. Ferguson III is reported as an officer of Mineralys Therapeutics (MLYS) with the title Chief Medical Officer. He is not listed as a director and not identified as a ten percent owner in this insider report.

Does the Mineralys Therapeutics (MLYS) Form 3 include any derivative securities for the CMO?

No. The derivativeSummary section is empty and the transaction summary lists zero derivative transactions, indicating that no options or other derivative securities are reported for James J. Ferguson III in this statement.

What is the significance of the Power of Attorney noted in the Mineralys (MLYS) Form 3?

The remarks reference an exhibit titled James J. Ferguson III Power of Attorney, indicating that a Power of Attorney has been granted for handling SEC reporting matters on his behalf, a common administrative arrangement for insiders.

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Ferguson James J. III

(Last) (First) (Middle)

150 N. RADNOR CHESTER ROAD

SUITE F200

(Street)

RADNOR PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/10/2026

3. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

EXHIBIT LIST: EX-24 James J. Ferguson III POA

No securities are beneficially owned.

	/s/ Jeffrey A. Munsie, attorney-in-fact	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)